Cargando…

Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives

Graves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ quality of life, causing severe social and psychological sequelae. Intravenous glucocorticosteroids is currently the mainstay of therapy, but the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Supronik, Jakub, Szelachowska, Małgorzata, Kretowski, Adam, Siewko, Katarzyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716394/ https://www.ncbi.nlm.nih.gov/pubmed/36219838 http://dx.doi.org/10.1530/EC-22-0303

Ejemplares similares

Tears as a Source of Biomarkers in the Diagnosis of Graves’ Orbitopathy
por: Bajkowska, Diana, et al.
Publicado: (2022)

MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives
por: Wielogórska, Marta, et al.
Publicado: (2022)

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
por: Şimşek, Tülay, et al.
Publicado: (2017)

Efficacy of (99m)Tc-DTPA SPECT/CT in diagnosing Orbitopathy in graves’ disease
por: Szumowski, Piotr, et al.
Publicado: (2019)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer
por: Rogucki, Mariusz, et al.
Publicado: (2022)

Applications of Metabolomics in Calcium Metabolism Disorders in Humans
por: Podgórska, Beata, et al.
Publicado: (2022)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Editorial: Mechanisms and Novel Therapies in Graves’ Orbitopathy: Current Update
por: Zhou, Huifang, et al.
Publicado: (2022)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Therapeutic Potential of Targeting Periostin in the Treatment of Graves’ Orbitopathy
por: Jang, Sun Young, et al.
Publicado: (2022)

Sirolimus as a second-line treatment for Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)

Novel Insight into Non-Genetic Risk Factors of Graves’ Orbitopathy
por: Zawadzka-Starczewska, Katarzyna, et al.
Publicado: (2022)

Cardiovascular risk factors in mild adrenal autonomous cortisol secretion in a Caucasian population
por: Adamska, Agnieszka, et al.
Publicado: (2022)

IgG4 as a Biomarker in Graves' Orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2021)

Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
por: Walasik-Szemplińska, Dorota, et al.
Publicado: (2019)

Imaging studies for diagnosing Graves' orbitopathy and dysthyroid optic neuropathy
por: Gonçalves, Allan C. Pieroni, et al.
Publicado: (2012)

Significance of HLA in Graves’ disease and Graves’ orbitopathy in Asian and Caucasian populations – a systematic review
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ghovvk23gbsrcoil4np7erdbr3